140 related articles for article (PubMed ID: 11012292)
1. [Switch strategy: replacing the protease inhibitor. Quality of life improves].
MMW Fortschr Med; 2000; 142(3 Suppl):37. PubMed ID: 11012292
[No Abstract] [Full Text] [Related]
2. Lipodystrophy--nukes vs. protease inhibitors.
TreatmentUpdate; 2001 Jul; 13(3):5-6. PubMed ID: 11569989
[No Abstract] [Full Text] [Related]
3. [Increased girth, thin arms. Unusual changes in HIV therapy].
MMW Fortschr Med; 1999 Sep; 141(36):62-3. PubMed ID: 10904607
[No Abstract] [Full Text] [Related]
4. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
[TBL] [Abstract][Full Text] [Related]
5. "Switch" studies for people with lipodystrophy.
Proj Inf Perspect; 2000 Aug; (30):9. PubMed ID: 12171017
[TBL] [Abstract][Full Text] [Related]
6. Lipodrama.
Horn T
Res Initiat Treat Action; 1999 Dec; 5(5):13-5. PubMed ID: 11366885
[TBL] [Abstract][Full Text] [Related]
7. AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
Bellman P
AIDS Treat News; 2000 Apr; (No 340):1-6. PubMed ID: 11367198
[TBL] [Abstract][Full Text] [Related]
8. Combination study of Invirase and Norvir starting.
AIDS Patient Care STDS; 1996 Jun; 10(3):187. PubMed ID: 11361633
[No Abstract] [Full Text] [Related]
9. Are changes in body shape due to drug side effects?
TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790
[TBL] [Abstract][Full Text] [Related]
10. Protease inhibitors raising quality-of-life issues for HIV patients.
Silversides A
CMAJ; 1999 Mar; 160(6):894. PubMed ID: 10189444
[No Abstract] [Full Text] [Related]
11. Strategies for protease inhibitor failure.
Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
[TBL] [Abstract][Full Text] [Related]
12. Focus on fat.
TreatmentUpdate; 2002 Nov; 14(8):4. PubMed ID: 12501822
[No Abstract] [Full Text] [Related]
13. A chat with HIV specialists: the Geneva report.
Newsline People AIDS Coalit N Y; 1998 Sep; ():12-7. PubMed ID: 11367483
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir and indinavir one year later.
TreatmentUpdate; 2001; 12(12):6-7. PubMed ID: 11570094
[No Abstract] [Full Text] [Related]
15. Amping amprenavir with ritonavir.
TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
[No Abstract] [Full Text] [Related]
16. Fat, sugar and drugs on the French Riviera.
Lands L
GMHC Treat Issues; 1999 Mar; 13(3):9-11. PubMed ID: 11366205
[TBL] [Abstract][Full Text] [Related]
17. Toxicity of antiretroviral therapy and implications for drug development.
Carr A
Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
[No Abstract] [Full Text] [Related]
18. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
19. [New treatment options for HIV-infected patients].
Wehr A
Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
[No Abstract] [Full Text] [Related]
20. Choosing the right initial antiretroviral regimens.
Norton M
GMHC Treat Issues; 1999 Feb; 13(2):7-10. PubMed ID: 11366117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
